Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

@article{Molina2010OncedailyAC,
  title={Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.},
  author={Jean Michel Molina and Jaime F Andrade-Villanueva and Juan Echevarr{\'i}a and Ploenchan Chetchotisakd and Jorge Corral and Neal David and Graeme Moyle and Marco Mancini and Lisa D Percival and Rong Yang and Victoria Wirtz and Max Lataillade and Judith Absalon and Donnie McGrath},
  journal={Journal of acquired immune deficiency syndromes},
  year={2010},
  volume={53 3},
  pages={323-32}
}
BACKGROUND Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal disturbance and a better lipid profile, in treatment-naive patients. METHODS International, multicenter, open-label, 96-week noninferiority randomized trial of atazanavir/ritonavir 300/100 mg once daily vs lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed-dose tenofovir/emtricitabine 300/200 mg once daily, in… CONTINUE READING
111 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 111 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

ARTEMIS: efficacy and safety of darunavir/ritonavir (DRV/r) 800/100 mg once-daily vs lopinavir/ritonavir (LPV/r) in treatment-naive, HIV-1-infected patients at 96 wks

  • A Mills, M Nelson, D Jayaweera
  • Presented at: 48th Interscience Conference on…
  • 2008
1 Excerpt

Efficacy and safety of abacavir/lamivudine combined to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study

  • K Smith, D Fine, P. Patel
  • Presented at: 15th Conference on Retrovirus and…
  • 2008

Efficacy and safety of once - daily darunavir / ritonavir versus lopinavir / ritonavir in treatment - naive HIV - 1 - infected patients at week 48

  • JM Molina, J Andrade-Villanueva, J Echevarria
  • AIDS
  • 2008

Similar Papers

Loading similar papers…